Close Menu

NEW YORK – Proscia said today that it has received the CE mark for its Concentriq Dx digital pathology software for use in primary diagnosis.

Concentriq Dx enables pathologists to make a primary diagnosis of cancers and other diseases from digitized images of patients' tissue biopsies, helping laboratories to deliver more timely, high-quality diagnoses, Proscia said.

Receipt of the CE mark accelerates its entry into the diagnostic pathology market in Europe and other key geographies globally to help laboratories keep pace with the rising cancer burden, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.